Seminars in Nephrology
Volume 28, Issue 3 , Pages 279-288 , May 2008

Vasopressin Antagonists in the Treatment of Water-Retaining Disorders

  • Sumit Kumar, MD, MPH

      Affiliations

    • Department of Nephrology, Presbyterian Hospital, Dallas, TX.
    • ,
  • Tomas Berl, MD

      Affiliations

    • Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado at Denver and Health Sciences Center, Denver, CO.
    • Corresponding Author InformationAddress reprint requests to Tomas Berl, MD, Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado at Denver and Health Sciences Center, 4200 E. Ninth Ave, Box C281, Denver, CO 80262.

References 

  1. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–1589
  2. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985;102:164–168
  3. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21:70–76
  4. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003;337:169–172
  5. Ellison DH, Berl T. Clinical practice (The syndrome of inappropriate antidiuresis). N Engl J Med. 2007;356:2064–2072
  6. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol. 1997;272:F3–F12
  7. Chen S, Jalandhara N, Batlle D. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Clin Pract. 2007;3:82–95
  8. Berl T, Schrier RW. Disorders of water balance. In:  Schrier RW editors. Renal and Electrolyte Disorders. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 1–63
  9. Thurman J, Halterman R, Berl T. Therapy of dysnatremic disorders (Therapy in nephrology and hypertension). 2nd ed. Philadelphia: WB Saunders; 2003;
  10. Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110–1117
  11. Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther. 2006;316:564–571
  12. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest. 1996;98:2729–2738
  13. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab. 1997;82:1054–1057
  14. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001;110:582–584
  15. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–191
  16. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006;1:1154–1160
  17. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112
  18. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91:2145–2152
  19. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447–457
  20. Walter KA. Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm. 2007;64:1385–1395
  21. Kumar S, Berl T. Sodium. Lancet. 1998;352:220–228
  22. Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean?. J Am Soc Nephrol. 2007;18:2028–2031
  23. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med. 2001;138:18–21
  24. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–939
  25. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–585
  26. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980–988
  27. Yancy CW. Climbing the mountain of acute decompensated heart failure: the EVEREST Trials. JAMA. 2007;297:1374–1376
  28. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–2696
  29. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971
  30. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–1331
  31. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  32. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615–1621
  33. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  34. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151–2159
  35. Verbalis JG. Vaptans for the treatment of hyponatremia: how, who, when and why. Nephrol Self Assessment Programs. 2007;6:199–209
  36. Furst H, Hallows KR, Post J, Chen S, Kotzker W, Goldfarb S, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000;319:240–244
  37. Kumar S, Berl T. Diseases of water metabolism. In:  Schrier RW,  Berl T editor. Atlas of diseases of the kidney. Blackwell Science: Philadelphia; 1999;p. 1–22
  38. Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiade M, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9–18

PII: S0270-9295(08)00053-3

doi: 10.1016/j.semnephrol.2008.03.008

Seminars in Nephrology
Volume 28, Issue 3 , Pages 279-288 , May 2008

Article Tools

* Image Usage & Resolution